NTRK3 and breast cancer: As result, NTRK3 expression was significantly associated with a better prognosis in BC, as evidenced by OS (HR = 0.6592, p = 0.012, Figure 3A), PFI (HR = 0.6833, p = 0.0291, Figure 3B), and progression-free survival (HR = 0.725, p = 0.0223, Figure 3C).